Actipulse Neuroscience Analysis
What is Actipulse Neuroscience?
Actipulse Neuroscience is a neuro-tech company developing non-invasive brain stimulation technologies for psychiatric and neurological disorders. Its website describes transcranial neuromodulation devices that use high-frequency magnetic pulses and a clinical pipeline for depression and other CNS conditions. The company says it is a Paris Brain Institute company and is backed by Y Combinator.
Location
210 Broadway, Cambridge, Massachusetts 02139, US
Employees
11-50
Founded
2017
Revenue
$174K-$2.9M
Business Model
Revenue from hospital devices and shared-revenue model for recurring income.
Company Stage
Seed
YC Batch
W22
Product Features & Capabilities
- Non-Invasive Brain Stimulation technologies, transcranial neuromodulation devices, treatment for Major Depressive Disorder, oncology applications.
Pricing
- Treatment with Actipulse Home is anticipated to cost between $1,200 and $1,600 for a duration of approximately 3 months.
Who are the founders of Actipulse Neuroscience
AC
Adrien Châtillon
Founder
GV
Gabriel Villafuerte
Founder
Market Focus
Actipulse Neuroscience primarily focuses on the healthcare industry, specifically in the field of psychiatric and neurological disorders through the development of Non-Invasive Brain Stimulation technologies.
Competitors Overview
Actipulse Neuroscience operates in the Non-Invasive Brain Stimulation market, focusing on transcranial neuromodulation devices for psychiatric and neurological disorders. Its main competitors include:
-
Emotra: Specializes in emotional assessment and treatment technologies, focusing on depression and anxiety disorders. Their approach emphasizes personalized treatment based on emotional responses.
-
Unyte: Offers a range of biofeedback and neurofeedback solutions aimed at improving mental health and cognitive function. Their products are designed for both clinical and personal use, providing a more holistic approach to mental wellness.
-
Walden Medical: Focuses on innovative medical devices for mental health treatment, including transcranial magnetic stimulation (TMS) devices. They emphasize the integration of technology with therapeutic practices.
-
Tombot: Develops robotic therapy companions aimed at improving mental health, particularly for elderly patients. Their unique approach combines robotics with emotional support, differentiating them from traditional neuromodulation devices.
-
Axovant Sciences Ltd: Engages in developing gene therapies for neurological diseases, providing a different angle in the treatment of neurological disorders compared to Actipulse's device-focused approach.
-
Bionaut Labs: Focuses on precision medicine and targeted delivery systems for neurological conditions, which may offer advantages in treatment specificity compared to broader neuromodulation techniques.
-
Cerevel Therapeutics: Works on developing therapies for neurodegenerative diseases, leveraging advanced drug development techniques that differ from Actipulse's device-centric model.
These competitors vary in their approaches, with some focusing on drug therapies while others emphasize device-based treatments or innovative therapeutic methods.
Investors
- Y Combinator
- MassChallenge
- FoundersX Ventures
- Trav Walkowski
- Empire Group International
Company Pricing
- Treatment with Actipulse Home is anticipated to cost between $1,200 and $1,600 for a duration of approximately 3 months.
See something that needs updating? Suggest edits to this profile.